Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com 3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com 3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com 3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com 4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com 4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 5 years ago
Magnolia Medical Captures $20M to Reduce Blood Culture Contamination
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com 5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com 5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com 6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines